|
Delayed
Australian S.E.
19:59:05 2026-09-28 EDT
|
5-day change | 1st Jan Change | ||
| 0.0100 AUD | +5.26% |
|
+11.11% | -33.33% |
| 08-26 | Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 08-24 | Acrux Limited Auditor Raises 'Going Concern' Doubt | CI |
Sales 2026 by Business Segment
Sales 2026 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: June | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Developing and Commercialising Pharmaceutical Products | 1.72M | 8.43M | 5.09M | 1.19M | 6.58M | |||||
Total Assets | 14.3M | 13.28M | 8.96M | 7.22M | 5.84M | |||||
Interest Expense | - | - | - | -303K | -282K | |||||
Income Tax Expense | 252K | 552K | 232K | 8K | 135K | |||||
CAPEX | -465K | -119K | -276K | -5K | - | |||||
EBT | -9.58M | -212K | -5.57M | -5.94M | -469K | |||||
D&A | 553K | 863K | 510K | 467K | 438K | |||||
Net Income | -9.83M | -764K | -5.8M | -5.94M | -604K |
| Fiscal Period: June | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Australia | 3.38M | 3.5M | 3.01M | 3.34M | 3.65M | |||||
Total Assets | - | - | - | - | - | |||||
United States of America | 299K | 1.14M | 4.47M | 1.19M | 2.95M | |||||
Europe and Other Countries | 1.42M | 7.29M | 622K | - | - | |||||
Germany | - | - | - | - | - | |||||
Switzerland | - | - | - | - | - | |||||
Other | - | - | - | - | - | |||||
| - | - | - | - | 2.95M | ||||||
| - | - | - | - | 3.65M |
- Stock Market
- Stocks
- ACR Stock
- Financials Acrux Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
